Ask AI
ProCE Banner Activity

Raising the Bar: Questions and Answers on Innovations in PBC Care

Clinical Thought

To learn more about how you can implement emerging clinical trial data on exciting new agents for primary biliary cholangitis (PBC) into your clinical practice, here are our answers to select learner questions from our recent satellite symposium, “Raising the Bar: Innovations in PBC Care.”

Released: December 18, 2025

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Gilead Sciences, Inc.

Gilead Sciences, Inc.

Target Audience

This activity is intended for physicians, including hepatologists and gastroenterologists, physician associates, nurse practitioners, and other HCPs involved in the care of patients with PBC.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Develop treatment goals for PBC that include evidence-based biochemical targets and improvement in symptoms and quality of life

  • Outline the role of new PBC therapies in achieving biochemical targets and symptom management

  • Design comprehensive treatment plans for patients with PBC

Disclosure

Primary Author

Christopher L. Bowlus, MD: researcher (paid to institution): Calliditas, ChemoMab, COUR, Cymabay, Gilead, GSK, Hanmi, Ipsen, Mirum, Novartis, Pliant, Zydus; consultant/advisor/speaker: Alnylam, Amgen, AstraZeneca, ChemoMab, Esperion, Gilead, GSK, Ipsen, Kezar, Mirum, Pliant, Takeda.

Aparna Goel, MD: consultant/advisor/speaker/researcher: Gilead, Ipsen, Mirum.

Aliya F. Gulamhusein, MD, MPH, FRCPC: consultant/advisor/speaker: Advanz, Gilead, Ipsen, Mirum.